Zoonosis update filovirus infections

Journal of the American Veterinary Medical Association

Volumn 234, Issue 9, 2009, Pages 1130-1138

  Warfield, Kelly L ^a   Deal, Emily M ^b   Bavari, Sina ^c  

^a Integrated BioTherapeutics Inc   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MARBURGVIRUS;

VIRUS VACCINE;

ANIMAL; DIFFERENTIAL DIAGNOSIS; DISEASE CARRIER; DISEASE TRANSMISSION; EPIDEMIC; FILOVIRIDAE; HUMAN; PATHOGENICITY; REVIEW; VIROLOGY; VIRUS INFECTION; ZOONOSIS;

ANIMALS; DIAGNOSIS, DIFFERENTIAL; DISEASE OUTBREAKS; DISEASE RESERVOIRS; FILOVIRIDAE; FILOVIRIDAE INFECTIONS; HUMANS; VIRAL VACCINES; ZOONOSES;

EID: 67649528670     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: 10.2460/javma.234.9.1130     Document Type: Article

References (123)

1. Feldmann H, Jones S, Klenk HD, et al. Ebola virus: from discovery to vaccine. Nat Rev Immunol 2003;3:677-685.
2. Cyranoski D. Ebola outbreak has experts rooting for answers. Nature 2009;457:364-365.
3. Jeffs B. A clinical guide to viral haemorrhagic fevers: Ebola, Marburg and Lassa. Trop Doct 2006;36:1-4.
4. Formenty P, Hatz C, Le Guenno B, et al. Human infection due to Ebola virus, subtype Cote d'lvoire: clinical and biologic presentation.; Infect Dis 1999;179(suppl 1):S48-S53.
5. Bwaka MA, Bonnet MJ, Calain P, et al. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J Infect Dis 1999;179(suppl 1):S1-S7.
6. Stroher U, West E, Bugany H, et al. Infection and activation of monocytes by Marburg and Ebola viruses. J Virol 2001 ;75:11025-11033.
7. Geisbert TW, Young HA, Jahrling PB, et al. Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis 2003;188:1618-1629.
8. Mahanty S, Hutchinson K, Agarwal S, et al. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J Immunol 2003;170:2797-2801.
9. Bosio CM, Aman MJ, Grogan C, et al. Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis 2003;188:1630-1638.
10. Geisbert TW, Hensley LE, Larsen T, et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 2003;163:2347-2370.
11. Gupta M, Mahanty S, Ahmed R, et al. Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with ebola virus secrete MlP-lalpha and TNF-alpha and inhibit poly-IC-induced IFN-alpha in vitro. Virology 2001;284:20-25.
12. Schnittler HJ, Feldmann H. Molecular pathogenesis of filovirus infections: role of macrophages and endothelial cells. Curr Top Microbiol Immunol 1999;235:175-204.
13. Bradfute SB, Braun DR, Shamblin JD, et al. Lymphocyte death in a mouse model of Ebola virus infection. J Infect Dis 2007;196(suppl 2):S296-S304.
14. Geisbert TW, Hensley LE, Gibb TR, et al. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest 2000;80:171-186.
15. Siegert R, Shu HL, Slenczka W Detection of the "Marburg virus" inpatients. Cer Med Mon 1968;13:521-524.
16. Martini GA, Knauff HG, Schmidt HA, et al. A hitherto unknown infectious disease contracted from monkeys. "Marburg-virus" disease. Ger Med Mon 1968;13:457-470.
17. Slenczka W, Klenk HD. Forty years of marburg virus. J Infect Dis 2007;196(suppl 2):S131-S135.
18. Hoenen T, Groseth A, Falzarano D, et al. Ebola virus: unravelling pathogenesis to combat a deadly disease. Trends Mol Med 2006;12:206-215.
19. Martini GA, Siegert R. Marburg virus disease. New York: Springer-Verlag Inc, 1971;230.
20. The new program of the World Health Organization in medical virology. Intervirology 1975;6:133-149.
21. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ 1978;56:271-293.
22. Isaacson M, Sureau P, Courteille G, et al. Clinical aspects of Ebola virus disease at the Ngaliema Hospital, Kinshasa, Zaire, 1976. In: Pattyn SR, ed. Ebola virus haemorrhagic fever. Amsterdam: Elsevier/North-Holland Biomedical Press, 1978;15-20.
23. Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team. Bull World Health Organ 1978;56:247-270.
24. Smith DH, Francis F, Simpson DIH. African haemorrhagic fever in the Southern Sudan, 1976: the clinical manifestations. In: Pattyn SR, ed. Ebola virus haemorrhagic fever. Amsterdam, The Netherlands: Elsevier/North-Holland Biomedical Press, 1978;21-26.
25. Emond RT, Evans B, Bowen ET, et al. A case of Ebola virus infection. Br Med J 1977;2:541-544.
26. Heymann DL, Weisfeld JS, Webb PA, et al. Ebola hemorrhagic fever: Tandala, Zaire, 1977-1978. J Infect Dis 1980;142:372-376.
27. Baron RC, McCormick JB, Zubeir OA. Ebola virus disease in southern Sudan: hospital dissemination and intrafamilial spread. Bull World Health Organ 1983;61:997-1003.
28. Smith DH, Johnson BK, Isaacson M, et al. Marburg-virus disease in Kenya. Lancet 1982;1:816-820.
29. Johnson ED, Johnson BK, Silverstein D, et al. Characterization of a new Marburg virus isolated from a 1987 fatal case in Kenya. Arch Virol Suppl 1996;11:101-114.
30. Jahrling PB, Geisbert TW, Dalgard DW, et al. Preliminary report: isolation of Ebola virus from monkeys imported to USA. Lancet 1990;335:502-505.
31. Rollin PE, Williams RJ, Bressler DS, et al. Ebola (subtype Reston) virus among quarantined nonhuman primates recently imported from the Philippines to the United States. J Infect Dis 1999;179(suppl 1):S108-S114.
32. Hayes CG, Burans JP, Ksiazek TG, et al. Outbreak of fatal illness among captive macaques in the Philippines caused by an Ebolarelated filovirus. Am J Trop Med Hyg 1992;46:664-671.
33. Miranda ME, White ME, Dayrit MM, et al. Seroepidemiological study of filovirus related to Ebola in the Philippines. Lancet 1991;337:425-426.
34. Georges AJ, Leroy EM, Renaut AA, et al. Ebola hemorrhagic fever outbreaks in Gabon, 1994-1997: epidemiologic and health control issues. J Infect Dis 1999;179(suppl 1):S65-S75.
35. Le Guenno B, Formenty P, Wyers M, et al. Isolation and partial characterisation of a new strain of Ebola virus (Erratum published in Lancet 2006;367:816). Lancet 1995;345:1271-1274.
36. Le Guenno B, Formenty P, Boesch C. Ebola virus outbreaks in the Ivory Coast and Liberia, 1994-1995. Curr Top Microbiol Immunol 1999;235:77-84.
37. Khan AS, Tshioko FK, Heymann DL, et al. The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis 1999;179(suppl 1):S76-S86.
38. Sidley P. Fears over Ebola spread as nurse dies. BMJ 1996;313:1351.
39. Miranda ME, Ksiazek TG, Retuya TJ, et al. Epidemiology of Ebola (subtype Reston) virus in the Philippines, 1996. J Infect Dis 1999;179(suppl 1):S115-S119.
40. Bausch DG, Nichol ST, Muyembe-Tamfum JJ, et al. Marburg hemorrhagic fever associated with multiple genetic lineages of virus. N Engl J Med 2006;355:909-919.
41. Okware SI, Omaswa FG, Zaramba S, et al. An outbreak of Ebola in Uganda. Trop Med Int Health 2002;7:1068-1075.
42. Bitekyerezo M, Kyobutungi C, Kizza R, et al. The outbreak and control of Ebola viral haemorrhagic fever in a Ugandan medical school. Trop Doct 2002;32:10-15.
43. Nkoghe D, Formenty P, Leroy EM, et al. Multiple Ebola virus haemorrhagic fever outbreaks in Gabon, from October 2001 to April 2002 [in French]. Bull Soc Pathol Exot 2005;98:224-229.
44. Rouquet P, Froment JM, Bermejo M, et al. Wild animal mortality monitoring and human Ebola outbreaks, Gabon and Republic of Congo, 2001-2003. Emerg Infect Dis 2005;11:283-290.
45. Formenty P, Libama F, Epelboin A, et al. Outbreak of Ebola hemorrhagic fever in the Republic of the Congo, 2003: a new strategy? [in French], Med Trop (Mars) 2003;63:291-295.
46. Milleliri JM, Tevi-Benissan C, Baize S, et al. Epidemics of Ebola haemorrhagic fever in Gabon (1994-2002). Epidemiologic aspects and considerations on control measures [in French]. Bull Soc Pathol Exot 2004;97:199-205.
47. CDC. Outbreak of Marburg virus hemorrhagic fever-Angola, October 1, 2004-March 29, 2005. MMWR Morb Mortal Wkly Rep 2005;54:308-309.
48. Towner JS, Khristova ML, Sealy TK, et al. Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola. J Virol 2006;80:6497-6516.
49. Outbreak news. Marburg haemorrhagic fever, Uganda. Wkly Epidemiol Rec 2007;82:297-298.
50. Outbreak news. Ebola virus haemorrhagic fever, Democratic Republic of the Congo-update. Wkly Epidemiol Rec 2007;82:345-346.
51. Outbreak news. Ebola haemorrhagic fever, Uganda-end of the outbreak. Wkly Epidemiol Rec 2008;83:89-90.
52. Alsop Z. Ebola outbreak in Uganda "atypical", say experts. Lancet 2007;370:2085.
53. Gonzalez JP, Pourrut X, Leroy E. Ebolavirus and other filoviruses. Curr Top Microbiol Immunol 2007;315:363-387.
54. Luby JP, Sanders CV. Green monkey disease ("Marburg virus" disease): a new zoonosis. Ann Intern Med 1969;71:657-660.
55. Formenty P, Boesch C, Wyers M, et al. Ebola virus outbreak among wild chimpanzees living in a rain forest of Cote d'lvoire. J Infect Dis 1999;179(suppl 1):S120-S126.
56. Walsh PD, Abernethy KA, Bermejo M, et al. Catastrophic ape decline in western equatorial Africa. Nature 2003;422:611-614.
57. Monath TP Ecology of Marburg and Ebola viruses: speculations and directions for future research. J Infect Dis 1999;179(suppl 1):S127-S138.
58. Peterson AT, Carroll DS, Mills JN, et al. Potential mammalian filovirus reservoirs. Emerg Infect Dis 2004;10:2073-2081.
59. Gonzalez JP, Herbreteau V, Morvan J, et al. Ebola virus circulation in Africa: a balance between clinical expression and epidemiological silence. Bull Soc Pathol Exot 2005;98:210-217.
60. Breman JG, Johnson KM, van der Groen G, et al. A search for Ebola virus in animals in the Democratic Republic of the Congo and Cameroon: ecologic, virologic, and serologic surveys, 1979-1980. Ebola virus study teams. J Infect Dis 1999;179(suppl 1): S139-S147.
61. Reiter P, Turell M, Coleman R, et al. Field investigations of an outbreak of Ebola hemorrhagic fever, Kikwit, Democratic Republic of the Congo, 1995: arthropod studies. J Infect Dis 1999;179(suppl 1):S148-S154.
62. Turell MJ, Bressler DS, Rossi CA. Short report: lack of virus replication in arthropods after intrathoracic inoculation of Ebola Reston virus. Am J Trap Med Hyg 1996;55:89-90.
63. Conrad JL, Isaacson M, Smith EB, et al. Epidemiologic investigation of Marburg virus disease, Southern Africa, 1975. Am J Trop Med Hyg 1978;27:1210-1215.
64. Nakazibwe C. Marburg fever outbreak leads scientists to suspected disease reservoir. Bull World Health Organ 2007,85:654-656.
65. Leirs H, Mills JN, Krebs JW, et al. Search for the Ebola virus reservoir in Kikwit, Democratic Republic of the Congo: reflections on a vertebrate collection. J Infect Dis 1999;179(suppl 1): S155-S163.
66. Groseth A, Feldmann H, StrongJE. The ecology of Ebola virus. Trends Microbiol 2007;15:408-416.
67. Leroy EM, Kumulungui B, Pourrut X, et al. Fruit bats as reservoirs of Ebola virus. Nature 2005;438:575-576.
68. Towner JS, Pourrut X, Albarino CG, et al. Marburg virus infection detected in a common African bat. PLoS ONE [serial online] . 2007;2:e764. Available at: www.plosone.org/home.action. Accessed Mar 30, 2009.
69. Jahrling PB, Geisbert TW, Jaax NK, et al. Experimental infection of cynomolgus macaques with Ebola-Reston filoviruses from the 1989-1990 US epizootic. Arch Virol Suppl 1996;11:115-134.
70. Morikawa S, Saijo M, Kurane I. Current knowledge on lower virulence of Reston Ebola virus (in French: Connaissances actuelles sur la moindre virulence du virus Ebola Reston). Comp Immunol Microbiol Infect Dis 2007;30:391-398.
71. CDC. Ebola-Reston virus infection among quarantined nonhuman primates-Texas, 1996. MMWR Morb Mortal Wkly Rep 1996;45:314-316.
72. Fisher-Hoch SP, Perez-Oronoz GI, Jackson EL, et al. Filovirus clearance in non-human primates. Lancet 1992;340:451-453.
73. Ebola virus infection in imported primates-United States. Can Dis Wkly Rep 1990;16:17-18.
74. CDC. Ebola virus infection in imported primates-Virginia, 1989. MMWR Morb Mortal Wkly Rep 1989;38:831-832, 837-838.
75. Feldmann H. Marburg hemorrhagic fever-the forgotten cousin strikes. N Engl J Med 2006;355:866-869.
76. Biek R, Walsh PD, Leroy EM, et al. Recent common ancestry of Ebola Zaire virus found in a bat reservoir. PLoS Pathog [serial online]. 2006;2:e90. Available at: www.plospathogens.org/ home.action. Accessed Mar 30, 2009.
77. Swanepoel R, Smit SB, Rollin PE, et al. Studies of reservoir hosts for marburgvirus. Emerg Infect Dis 2007;13:1847-1851.
78. Gupta M, Mahanty S, Greer P, et al. Persistent infection with ebola virus under conditions of partial immunity. J Virol 2004;78:958-967.
79. Strong JE, Wong G, Jones SE, et al. Stimulation of Ebola virus production from persistent infection through activation of the Ras/MAPK pathway. Proc Natl Acad Sci USA 2008;105:17982-17987.
80. Jones KE, Patel NG, Levy MA, et al. Global trends in emerging infectious diseases. Nature 2008;451:990-993.
81. Fevre EM, Bronsvoort BM, Hamilton KA, et al. Animal movements and the spread of infectious diseases. Trends Microbiol 2006;14:125-131.
82. Eves HE. The bushmeat trade in Africa: conflict, consensus and collaboration. In: Levigne DM, ed. Gaining ground in pursuit of ecological sustamability. Limerick, Ireland: International Fund for Animal Welfare, Guelph, Canada, and the University of Limerick, 2006;141-152.
83. Chevalier V, de la Rocque S, Baldet T, et al. Epidemiological processes involved in the emergence of vector-borne diseases: West Nile fever, Rift Valley fever, Japanese encephalitis and Crimean- Congo haemorrhagic fever. Rev Sci Tech 2004;23:535-555.
84. Towner JS, Sealy TK, Khristova ML, et al. Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog [serial online]. 2008;4:el000212. Available at: www. plospathogens.org/home.action. Accessed Mar 30, 2009.
85. Daszak P, Epstein JH, Kilpatrick AM, et al. Collaborative research approaches to the role of wildlife in zoonotic disease emergence. Curr Top Microbiol Immunol 2007;315: 463-475.
86. Chretien JP, Blazes DL, Gaydos JC, et al. Experience of a global laboratory network in responding to infectious disease epidemics. Lancet Infect Dis 2006;6:538-540.
87. Miranda ME, Yoshikawa Y, Manalo DL, et al. Chronological and spatial analysis of the 1996 Ebola Reston virus outbreak in a monkey breeding facility in the Philippines. Exp Anim 2002;51:173-179.
88. DeMarcus TA, Tipple MA, Ostrowski SR. US policy for disease control among imported nonhuman primates. J Infect Dis 1999;179(suppl 1):S281-S282.
89. Geisbert TW, Hensley LE, Jahrling PB, et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor Vila/tissue factor; a study in rhesus monkeys. Lancet 2003;362:1953-1958.
90. Hensley LE, Stevens EL, Yan SB, et al. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis 2007;196(suppl 2):S390-S399.
91. Daddario-DiCaprio KM, Geisbert TW, Stroher U, et al. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet 2006,367:1399-1404.
92. Jones SM, Stroher U, Fernando L, et al. Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. J Infect Dis 2007;196(suppl 2): S404-S412.
93. Feldmann H, Jones SM, Daddario-Dicaprio KM, et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog [serial online]. 2007;3:e2. Available at: www.plospathogens.org/home. action. Accessed Mar 30, 2009.
94. Warfield KL, Swenson DL, dinger GG, et al. Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog [serial online]. 2006;2:el. Available at: www.plospathogens.org/home. action. Accessed Mar 30, 2009.
95. Baize S, Leroy EM, Georges-Courbot MC, et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med 1999;5:423-426,
96. Mohamadzadeh M, Chen L, dinger GG, et al. Filoviruses and the balance of innate, adaptive, and inflammatory responses. Viral Immunol 2006;19:602-612.
97. Chepurnov AA, Chuev Iu P P'lankov OV, et al. The effect of some physical and chemical factors on inactivation of the Ebola virus [in Russian). Vopr Virusol 1995;40:74-76.
98. Lupton HW. Inactivation of Ebola virus with 60Co irradiation. J Infect Dis 1981:143:291.
99. Lupton HW, Lambert RD, Bumgardner DL, et al. Inactivated vaccine for Ebola virus efficacious in guineapig model. Lancet 1980;2:1294-1295.
100. Mikhailov VV, Borisevich IV, Chernikova NK, et al. The evaluation in hamadryas baboons of the possibility for the specific prevention of Ebola fever [in Russian]. Vopr Virusol 1994;39:82-84.
101. Geisbert TW, Pushko P, Anderson K, et al. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis 2002;8:503-507.
102. Reed DS, Mohamadzadeh M. Status and challenges of filovirus vaccines. Vaccine 2007;25:1923-1934.
103. Agafonov AP, Ignat'ev GM, Kuz'min VA, et al. The immunogenic properties of Marburg virus proteins [in Russian], Vopr Virusol 1992;37:58-61.
104. Hevey M, Negley D, Geisbert J, et al. Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants. Virology 1997;239:206-216.
105. Vanderzanden L, Bray M, Fuller D, et al. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology 1998;246:134-144.
106. Hevey M, Negley D, Pushko P, et al. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 1998;251:28-37.
107. Jones SM, Feldmann H, Stroher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005;11:786-790.
108. Sullivan NJ, Geisbert TW, Geisbert JB, et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003;424:681-684.
109. Bukreyev A, Rollin PE, Tate MK, et al. Successful topical respiratory tract immunization of primates against Ebola virus. J Virol 2007;81:6379-6388.
110. Swenson DL, Warfield KL, Kuehl K, et al. Generation of Marburg virus-like particles by co-expression of. glycoprotein and matrix protein. FEMS Immunol Med Microbiol 2004;40:27-31.
111. Swenson DL, Warfield KL, Larsen T, et al. Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses. Expert Rev Vaccines 2008;7:417-429.
112. Swenson DL, Warfield KL, Negley DL, et al. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine 2005;23:3033-3042.
113. Warfield KL, Swenson DL, Olinger GG, et al. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 2007;196(suppl 2):S430- S437.
114. Warfield KL, Bosio CM, Welcher BC, et al. Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci U S A 2003;100:15889-15894.
115. Warfield KL, Olinger G, Deal EM, et al. Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. J Immunol 2005;175;1184-1191.
116. Warfield KL, Perkins JG, Swenson DL, et al. Role of natural killer cells in innate protection against lethal ebola virus infection. J Exp Med 2004;200:169-179.
117. Warfield KL, Posten NA, Swenson DL, et al. Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents. J Infect Dis 2007;196(suppl 2):S421-S429.
118. Warfield KL, Swenson DL, Demmin G, et al. Filovirus-hke particles as vaccines and discovery tools. Expert Rev Vaccines 2005;4:429-440.
119. Warfield KL, Swenson DL, Negley DL, et al. Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection. Vaccine 2004;22:3495-3502.
120. Noad R, Roy R Virus-like particles as immunogens. Trends Microbiol 2003;11:438-444.
121. Stanley MA. Human papillomavirus vaccines. Curr Opin Mol Ther 2002;4:15-22.
122. Harro CD, Pang YY, Roden RB, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 LI viruslike particle vaccine. J Natl Cancer Inst 2001;93:284-292.
123. Martin SJ, Vyakarnam A, Cheingsong-Popov R, et al. Immunization of human HIV-seronegative volunteers with recombinant pl7/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses. AIDS 1993;7:1315-1323.